Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson's Disease Published in JAMA Neurology
19 juin 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 19, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the...
Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline
24 mai 2018 09h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the...
Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update
08 mai 2018 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones...
Prothena to Report First Quarter 2018 Financial Results on May 8
01 mai 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the...
Prothena Discontinues Development of NEOD001 for AL Amyloidosis
23 avr. 2018 08h00 HE
|
Prothena Corporation plc
Phase 2b PRONTO study did not meet its primary or secondary endpointsPhase 3 VITAL Amyloidosis Study being discontinued based on futility analysisInvestor conference call and webcast today at 8:30 AM...
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
20 mars 2018 16h05 HE
|
Prothena Corporation plc
Prothena to receive a $100 million upfront payment and a $50 million equity investment by Celgene, with potential license payments and regulatory and commercial milestones, plus additional royalties...
Prothena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis
12 mars 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Participate in the Barclays Global Healthcare Conference
07 mars 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update
14 févr. 2018 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $39.9 million in the fourth quarter and $134.7 million for the full year 2017; quarter-end cash and restricted cash position of $421.7 million...
Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
07 févr. 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...